CSL posts bumper profit but top-line growth to slow

Biotech giant CSL is forecasting annual double-digit earnings growth for the next five years following a recovery in margins in its core plasma collection business, but its vaccine and pharmaceutical operations will slow revenue growth near-term.

CSL chief executive Paul McKenzie said on Tuesday that the company was on track to get margins back to pre-pandemic levels at the core Behring business which collects and processes blood plasma, but there was still more work to do.